Thermo Fisher Scientific Inc. Promotes Fred Lowery to Executive Vice President and President, Laboratory Products & BioProduction
Thermo Fisher Scientific Inc. promotes Fred Lowery to Executive Vice President and President, Laboratory Products and BioProduction.
Mr. Lowery has served as Executive Vice President and President, Laboratory Products and BioProduction, of Thermo Fisher Scientific Inc. since April 2024. Since joining Thermo Fisher in 2005, he has held several senior leadership positions across Thermo Fisher, including previously serving as Senior Vice President and President, Life Sciences Solutions and Laboratory Products, and Senior Vice President and President, Customer Channels. Prior to his time at Thermo Fisher, Mr. Lowery was with Maytag Corporation from 1999 to 2005 and began his career as an engineer at General Motors Company. Mr. Lowery is a member of the Board of Trustees for Boston Medical Center. He is also on the Board of Trustees for both Tennessee Tech and its Foundation. Mr. Lowery joined the DuPont Board of Directors in June 2019.
Skills and Expertise:
With his engineering and science backgrounds, Mr. Lowery brings science and technology perspective combined with senior management capabilities to the Board. Mr. Lowery has a wealth of global experience and has developed operating teams, launched innovative new products and acquired businesses. Additionally, he brings significant manufacturing and global supply chain knowledge and experience.
Shifting focus to the kind of workflow efficiencies that microbiology departments are increasingly prioritising, the cultivation of anaerobic and microaerophilic bacteria is an area where the right equipment pays dividends quickly. Having seen firsthand how much time is lost when gas packs fail to achieve the correct atmospheric conditions, I can appreciate why so many labs are exploring automated alternatives. A system designed around anaerobic bacterial cultivation and oxygen-depleted incubation jars removes a significant layer of variability from the process, meaning technicians spend less time troubleshooting and more time producing accurate, timely results. When the environmental conditions are dialled in correctly and held stable for the full incubation window, the clinical impact is measurable, particularly in reducing false negatives that can delay patient diagnosis.